6 O
ADVERSE O
REACTIONS O
The O
most O
commonly O
reported O
adverse O
reactions O
are O
hypersensitivity B-OSE_Labeled_AE
( O
e.g. O
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
) O
reactions O
due O
to O
the O
effect O
of O
GH O
( O
e.g. O
, O
arthralgia B-OSE_Labeled_AE
, O
extremity B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
pruritus O
, O
pain O
, O
urticaria O
, O
irritation O
, O
swelling O
, O
hemorrhage O
) O
. O

During O
the O
first O
26 O
weeks O
of O
treatment O
( O
main O
phase O
) O
, O
discontinuations O
as O
a O
result O
of O
adverse O
reactions O
occurred O
in O
9.6 O
% O
of O
patients O
receiving O
EGRIFTA O
( O
r O
) O
and O
6.8 O
% O
of O
patients O
receiving O
placebo O
. O

Apart O
from O
patients O
with O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
identified O
during O
the O
studies O
and O
who O
were O
discontinued O
per O
protocol O
( O
2.2 O
% O
) O
, O
the O
most O
common O
reasons O
for O
discontinuation O
of O
EGRIFTA O
( O
r O
) O
treatment O
were O
adverse O
reactions O
due O
to O
the O
effect O
of O
GH O
( O
4.2 O
% O
) O
and O
local O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
4.6 O
% O
) O
. O

During O
the O
following O
26 O
weeks O
of O
treatment O
( O
extension O
phase O
) O
, O
discontinuations O
as O
a O
result O
of O
adverse O
events O
occurred O
in O
2.4 O
% O
of O
patients O
in O
the O
T-T O
group O
( O
patients O
treated O
with O
tesamorelin O
for O
Week O
0-26 O
and O
with O
tesamorelin O
for O
Week O
26-52 O
) O
and O
5.2 O
% O
of O
patients O
in O
the O
T-P O
group O
( O
patients O
treated O
with O
tesamorelin O
for O
Week O
0-26 O
and O
with O
placebo O
for O
Week O
26-52 O
) O
. O

EXCERPT O
: O
Most O
commonly O
reported O
adverse O
reactions O
( O
> O
5 O
% O
and O
more O
frequent O
than O
placebo O
) O
: O
Arthralgia O
, O
injection O
site O
erythema O
, O
injection O
site O
pruritus O
, O
pain O
in O
extremity O
, O
peripheral O
edema O
, O
and O
myalgia O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
EGRIFTA O
ASSIST O
TM O
toll O
free O
at O
1-844-EGRIFTA O
( O
1-844-347-4382 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Seven O
hundred O
and O
forty O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
infected I-Not_AE_Candidate
patients I-Not_AE_Candidate
with I-Not_AE_Candidate
lipodystrophy I-Not_AE_Candidate
and O
excess B-Not_AE_Candidate
abdominal I-Not_AE_Candidate
fat I-Not_AE_Candidate
were O
exposed O
to O
EGRIFTA O
( O
r O
) O
in O
the O
Phase O
3 O
clinical O
trials O
; O
of O
these O
543 O
received O
EGRIFTA O
( O
r O
) O
during O
the O
initial O
26-week O
placebo-controlled O
phase O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Adverse O
reactions O
that O
occurred O
more O
frequently O
with O
EGRIFTA O
( O
r O
) O
relative O
to O
placebo O
and O
had O
an O
incidence O
> O
=1 O
% O
during O
the O
first O
26 O
weeks O
across O
all O
studies O
are O
presented O
in O
Table O
1 O
. O

Table O
1 O
. O

Adverse O
Reactions O
Reported O
in O
> O
= O
1 O
% O
and O
More O
Frequent O
in O
EGRIFTA O
( O
r O
) O
-treated O
than O
Placebo O
Patients O
during O
the O
26-Week O
Main O
Phase O
( O
Combined O
Studies O
) O
Incidence O
of O
patients O
( O
% O
) O
with O
adverse O
drug O
reactions O
System O
Organ O
Class O
Preferred O
Term O
EGRIFTA O
( O
r O
) O
( O
N=543 O
) O
Placebo O
( O
N=263 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
Myalgia B-OSE_Labeled_AE
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
Joint B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
Joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
13.36.15.51.81.71.51.11.1 O
11.04.61.90.80.40.80.80.0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
urticaria I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
8.57.66.14.12.91.71.71.71.51.31.11.1 O
2.70.82.33.01.11.10.40.40.40.80.80.0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Paresthesia B-OSE_Labeled_AE
Hypoesthesia B-OSE_Labeled_AE
Carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
4.84.21.5 O
2.31.50.0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
Dyspepsia B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
4.42.61.71.1 O
3.80.00.80.8 O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
1.1 O
0.4 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Depression B-OSE_Labeled_AE
2.0 O
1.5 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
Pruritus B-OSE_Labeled_AE
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
3.72.41.1 O
1.51.10.4 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
1.3 O
0.8 O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Muscle B-OSE_Labeled_AE
strain I-OSE_Labeled_AE
1.1 O
0.0 O
Investigations B-NonOSE_AE
Blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
1.5 O
0.4 O
Mean O
levels O
of O
fasting O
blood O
glucose O
and O
fasting O
insulin O
were O
not O
significantly O
different O
between O
EGRIFTA O
( O
r O
) O
-treated O
and O
placebo-treated O
patients O
after O
26 O
weeks O
of O
treatment O
. O

In O
the O
EGRIFTA O
( O
r O
) O
Phase O
3 O
clinical O
trials O
, O
mean O
baseline O
( O
Week O
0 O
) O
HbA1cwas O
5.26 O
% O
among O
patients O
in O
the O
EGRIFTA O
( O
r O
) O
group O
and O
5.28 O
% O
among O
those O
in O
the O
placebo O
group O
. O

At O
Week O
26 O
, O
mean O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
cwas I-OSE_Labeled_AE
higher I-OSE_Labeled_AE
among O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
compared O
with O
placebo O
( O
5.39 O
% O
vs O
. O
5.28 O
% O
for O
the O
EGRIFTA O
( O
r O
) O
and O
placebo O
groups O
, O
respectively O
, O
mean O
treatment O
difference O
of O
0.12 O
% O
, O
p=0.0004 O
) O
. O

Patients O
receiving O
EGRIFTA O
( O
r O
) O
had O
an O
increased O
risk O
of O
developing O
diabetes B-OSE_Labeled_AE
( O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
clevel I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
) O
compared O
with O
placebo O
( O
4.5 O
% O
vs O
. O
1.3 O
% O
) O
, O
with O
a O
hazard O
ratio O
of O
3.3 O
( O
CI O
1.4 O
, O
9.6 O
) O
. O

Adverse O
reactions O
observed O
during O
Week O
26 O
to O
52 O
of O
the O
Phase O
3 O
clinical O
trials O
which O
had O
an O
incidence O
of O
> O
=1 O
% O
and O
were O
seen O
more O
frequently O
with O
EGRIFTA O
( O
r O
) O
relative O
to O
placebo O
are O
presented O
in O
Table O
2 O
: O
Table O
2 O
. O

Adverse O
Reactions O
Reported O
in O
> O
= O
1 O
% O
and O
More O
Frequent O
in O
EGRIFTA O
( O
r O
) O
-treated O
than O
Placebo O
Patients O
during O
the O
26-Week O
Extension O
Phase O
of O
the O
Combined O
Studies O
( O
Week O
26 O
to O
Week O
52 O
of O
the O
studies O
) O
1T-T O
= O
tesamorelin O
for O
Week O
0-26 O
and O
tesamorelin O
for O
Week O
26-52 O
2T-P O
= O
tesamorelin O
for O
Week O
0-26 O
and O
placebo O
for O
Week O
26-52 O
For O
patients O
who O
continued O
from O
Week O
26-52 O
, O
mean O
levels O
of O
fasting B-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
, O
fasting B-NonOSE_AE
insulin I-NonOSE_AE
, O
and O
HbA B-NonOSE_AE
1 I-NonOSE_AE
c I-NonOSE_AE
were O
not O
different O
between O
the O
T-T O
and O
T-P O
groups O
. O

Incidence O
of O
patients O
( O
% O
) O
with O
adverse O
drug O
reactions O
System O
Organ O
Class O
Preferred O
Term O
T-T O
1 O
( O
Week O
26-52 O
) O
( O
N=246 O
) O
T-P O
2 O
( O
Week O
26-52 O
) O
( O
N=135 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
Myalgia B-OSE_Labeled_AE
3.31.2 O
0.70.0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
2.02.01.2 O
0.00.00.0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Paresthesia B-OSE_Labeled_AE
Hypoesthesia B-OSE_Labeled_AE
Neuropathy B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
1.61.61.6 O
1.50.71.5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
2.0 O
0.7 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Depression B-OSE_Labeled_AE
Insomnia B-OSE_Labeled_AE
1.61.2 O
0.70.0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
Urticaria B-OSE_Labeled_AE
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
1.21.21.2 O
0.70.00.0 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
Hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
1.61.2 O
1.50.7 O
6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
and O
peptides O
, O
there O
is O
a O
potential O
for O
in O
vivo O
development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
EGRIFTA I-OSE_Labeled_AE
( I-OSE_Labeled_AE
r I-OSE_Labeled_AE
) I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

In O
the O
combined O
Phase O
3 O
clinical O
trials O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
IgG I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected O
in O
49.5 O
% O
of O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
for O
26 O
weeks O
and O
47.4 O
% O
of O
patients O
who O
received O
EGRIFTA O
( O
r O
) O
for O
52 O
weeks O
. O

In O
the O
subset O
of O
patients O
with O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
IgG I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were I-OSE_Labeled_AE
detected I-OSE_Labeled_AE
in O
85.2 O
% O
. O

Cross B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reactivity I-OSE_Labeled_AE
to I-OSE_Labeled_AE
endogenous I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
- I-OSE_Labeled_AE
releasing I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
GHRH I-OSE_Labeled_AE
) O
was O
observed O
in O
approximately O
60 O
% O
of O
patients O
who O
developed O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

Patients O
with O
and O
without O
anti B-NonOSE_AE
- I-NonOSE_AE
tesamorelin I-NonOSE_AE
IgG I-NonOSE_AE
antibodies I-NonOSE_AE
had O
similar O
mean O
reductions B-NonOSE_AE
in I-NonOSE_AE
visceral I-NonOSE_AE
adipose I-NonOSE_AE
tissue I-NonOSE_AE
( I-NonOSE_AE
VAT I-NonOSE_AE
) O
and O
IGF B-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
response I-NonOSE_AE
suggesting O
that O
the O
presence B-NonOSE_AE
of I-NonOSE_AE
antibodies I-NonOSE_AE
did O
not O
alter O
the O
efficacy O
of O
EGRIFTA O
( O
r O
) O
. O

In O
a O
group O
of O
patients O
who O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
after O
26 O
weeks O
of O
treatment O
( O
56 O
% O
) O
and O
were O
re-assessed O
6 O
months O
later O
, O
after O
stopping O
EGRIFTA O
( O
r O
) O
treatment O
, O
18 O
% O
were O
still O
antibody B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
. O

Neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
and O
hGHRH O
were O
detected O
in O
vitro O
at O
Week O
52 O
in O
10 O
% O
and O
5 O
% O
of O
EGRIFTA O
( O
r O
) O
-treated O
patients O
, O
respectively O
. O

They O
did O
not O
appear O
to O
have O
an O
impact O
on O
efficacy O
, O
as O
evidenced O
by O
comparable O
changes O
in O
VAT O
and O
IGF-1 O
level O
in O
patients O
with O
or O
without O
in O
vitro O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
. O

The O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
including O
assay O
sensitivity O
and O
specificity O
, O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medication O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
EGRIFTA I-NonOSE_AE
( O
r O
) O
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

